Inside GLP 1 Data: An expert roundtable on mortality, morbidity, and risk
Presented by RGA
GLP‑1 therapies are emerging as a critical area of focus for both population health and insurance risk. In this roundtable, RGA’s biometric experts examine the latest research and early evidence, unpacking what these therapies could mean in an evolving and uncertain landscape.
Key takeaways:
- Shifting mortality outlook: There is growing expectation that GLP‑1 therapies, initially developed for diabetes and now widely used for weight loss, could meaningfully influence future mortality trends.
- Real‑world reality check: While clinical trial data is compelling, factors such as cost, adherence challenges, and side effects are likely to temper real‑world outcomes.
- Implications for insurers: These dynamics introduce variability across markets, populations, and uptake levels, shaping how and when benefits may emerge.
As the landscape evolves, insurers will need flexible, adaptive frameworks to incorporate new evidence and respond to changing risk profiles over time.
Partners